Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical Company Limited, formerly known as Shandong Xinhua Pharmaceutical Factory that was established in 1943 at Jiaodong Anti-Japanese Base, is a selected large-scale backbone pharmaceutical company in the PRC, the primary producer and exporter of analgesics in Asia and an important manufacturer in China for the drugs for cardio cerebrovascular system, anti-infection and central nervous system, with a relatively leading position and great influence in the chemical and pharmaceutical industry in the PRC. The Company was awarded one of the top 10 enterprises for technological innovation of the pharmaceutical industry in the PRC and one of the top 50 enterprises of the pharmaceutical industry in the PRC. The Company has formed a comprehensive industry chain of medical intermediate, bulk pharmaceuticals and preparations, equipped with strong supporting capability for products. 6 bulk pharmaceuticals such as ibuprofen and aspirin have been leading the market, with national top rankings in terms of market shares for many years. 8 major varieties of bulk pharmaceuticals such as Tribendimidine and Etofesalamide are exclusively manufactured in the country. Leveraging on strong scientific research and development capability and technological edges , the Company is a national high and new technology enterprise, a key high and new technology enterprise under the National Torch Program, and a key enterprise in the bio-pharmaceutical industrial base under the National Torch Program. The Company has a national-level enterprise technology centre and an enterprise post-doctoral research station. The Company maintains technology exchange and cooperation with scientific research institutes and well-established pharmaceutical enterprises, etc. The Company carries out the “Industry-University-Research” cooperative model with China Pharmaceutical University, Shenyang Pharmaceutical University, Shandong University, Institute of Medicinal Biotechnology under the Chinese Academy of Medical Sciences, National Institute of Parasitic Diseases of Chinese Center for Disease Control and Prevention and Qingdao University of Science & Technology and other units, endeavoring to conduct research and development in joint efforts of new drug technologies. Steady advancement of international strategies. 27 items of the Company, including ibuprofen and aspirin, have passed the American FDA certification, and 16 items, including caffeine and Annaijin Metamizole Sodium have passed the audit conducted by European EDQM. With a number of products are in leading positions in terms of market shares, the Company ranked amongst the top five exporters of Western medicine raw materials in the country. The Company’s tablets have passed the audit conducted by Medicines and Healthcare products Regulatory Agency, while injections have passed the audit conducted by International Dispensary Association, being one of the first 15 pioneering enterprises in the PRC which implement a global strategy and one of the top ten pharmaceutical exporters. The Company took the lead to be in line with international standards in terms of quality system and technological standards, while major subsidiaries have passed the ISO9001 and ISO14001 certifications. The Company vigorously implements international certification for pharmaceuticals to guide the production in accordance with the American and European cGMP standards, with hundreds of quality audits from customers conducted on an annual basis and all of them were passed.